IGMS Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 107997 min ago

@ $15.41

Ausgestellt: 14 Feb 2024 @ 19:56

Rendite: -35.82%

Vorheriges Signal: Feb 14 - 15:30

Vorheriges Signal: Verkaufen

Rendite: -4.82 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 20:54):

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases...

Stats
Tagesvolumen	460 675
Durchschnittsvolumen	282 635
Marktkapitalisierung	582.99M
EPS	$0 ( 2024-03-28 )
Nächstes Ertragsdatum	( $-0.840 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.10
ATR14	$0.0280 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Harler Mary Beth	Sell	0	Common Stock
2024-04-14	Harler Mary Beth	Sell	200 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	75 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	52 500	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	92 500	Stock Option (right to buy)

INSIDER POWER
56.95
Last 99 transactions
Buy: 2 356 293 \| Sell: 614 616

Volumen Korrelation

Lang: 0.03 (neutral)

Kurz: -0.65 (weak negative)

Signal:(37.726) Neutral

IGM Biosciences Inc Korrelation

10 Am meisten positiv korreliert
LWAC	0.811

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

IGM Biosciences Inc Korrelation - Währung/Rohstoff

0.12
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.60
( weak negative )

0.03
( neutral )

0.79
( moderate )

IGM Biosciences Inc Finanzdaten

Annual	2023
Umsatz:	$2.13M
Bruttogewinn:	$-6.15M (-288.59 %)
EPS:	$-4.71

FY	2023
Umsatz:	$2.13M
Bruttogewinn:	$-6.15M (-288.59 %)
EPS:	$-4.71

FY	2022
Umsatz:	$1.07M
Bruttogewinn:	$-9.53M (-891.77 %)
EPS:	$-5.16

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-5.37

Financial Reports:

No articles found.

IGM Biosciences Inc

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.